<DOC>
	<DOCNO>NCT02576314</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , efficacy Sofosbuvir contain regimen treatment-naive treatment-experienced patient HCV genotype 3 infection .</brief_summary>
	<brief_title>Sofosbuvir Containing Regimens Treatment Chronic HCV GT3 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Age equal great 18 year , chronic genotype 3 HCV infection ; Documented HCV treatmentnaïve treatmentexperienced subject fail previous PEG+RBV regimen ; HCV RNA &gt; 10,000 IU/mL Screening ; Screening laboratory value within defined threshold ; Negative pregnancy test baseline ( female childbearing potential ) ; Use two effective contraception method female childbearing potential sexually active male . Pregnant nursing female ; HIV infection HBV infection ( HBcAb HBsAg positive ) ; Hematologic biochemical parameter Screening outside protocolspecified requirement ; Active recent history ( ≤ 1 year ) drug alcohol abuse ; Hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>